A Multicenter, Open-label, Single-arm, Phase II Clinical Trial of Nab-paclitaxel in Combination With Pyrotinib in Adjuvant Therapy for Lymph Node-negative and Small Tumor HER2-positive Breast Cancer
Latest Information Update: 13 Feb 2023
At a glance
- Drugs Paclitaxel (Primary) ; Pyrotinib (Primary)
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms PHAEDRA
- 14 Mar 2022 Trial design published in the BMC Cancer
- 10 Dec 2021 Status changed from not yet recruiting to recruiting, as per Trial design presented at the 44th Annual San Antonio Breast Cancer Symposium
- 10 Dec 2021 Trial design, presented at the 44th Annual San Antonio Breast Cancer Symposium